Denali Therapeutics Inc. Initial Public Offering

Davis Polk advised the underwriters in connection with an initial public offering of 15,972,221 shares of common stock of Denali Therapeutics Inc., including shares sold pursuant to the full exercise of the underwriters’ over-allotment option, at $18.00 per share, for total gross proceeds of $287 million. Denali Therapeutics’ common stock is traded on the NASDAQ Global Select Market under the symbol “DNLI.” 

Headquartered in South San Francisco, California, Denali Therapeutics is a biopharmaceutical company focused on the discovery and development of therapies for patients with neurodegenerative disease.  

The Davis Polk corporate team included partners Alan F. Denenberg and Stephen Salmon and associates Connie Y. Lam and Josephine Chen. Counsel David R. Bauer and associates Bonnie Chen provided intellectual property and technology advice. Partner Mario J. Verdolini and associate Catherine L. Chu provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.